Wasting Syndrome (Cachexia) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Wasting Syndrome (Cachexia) Market Outlook

Thelansis’s “Wasting Syndrome (Cachexia) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wasting Syndrome (Cachexia) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Wasting Syndrome (Cachexia) Overview

Cachexia is a complex metabolic syndrome that arises from an underlying illness and is characterized by the loss of muscle mass, with or without the loss of fat mass. It often presents with anorexia, an inflammatory process, insulin resistance, and increased protein turnover. Cachexia leads to weight loss and an elevated risk of mortality. The primary cause of cachexia is an excess of cytokines. Additional contributing factors include deficiencies in testosterone and insulin-like growth factor-I, overabundance of myostatin, and excess glucocorticoids. Cachexia is distinguished by a persistent increase in the body's basal metabolic rate that is not compensated by an adequate intake of calories and protein. Various factors contribute to this abnormal metabolic cascade, including digestive issues, tumor-related factors, and hormonal responses to the underlying disease. Digestive factors that contribute to poor intake include dysgeusia (distorted sense of taste), nausea, dysphagia (difficulty swallowing), mucositis (inflammation of the mucous membranes), and constipation.

Cachexia is categorized into pre-cachexia, cachexia, and refractory cachexia. The consensus definitions for these stages are as follows:

1. Pre-cachexia: characterized by a weight loss of more than 1kg but less than 5%
2. Cachexia: indicated by a weight loss of more than 5% or a weight loss of more than 2% with a body mass index (BMI) below 20kg/m^2
3. Refractory cachexia: defined by a weight loss of more than 15% with a BMI below 23kg/m^2 or a weight loss of more than 20% with a BMI below 27kg/m^2

Differential diagnoses for cachexia include the following conditions: Celiac disease, Crohn's disease, Cystic fibrosis, Dementia, Mercury poisoning, Motor neuron disease, Multiple sclerosis, Multiple systems, trophy, Parkinson's disease, and Rheumatoid arthritis.

• The prevalence of cancer cachexia in the USA was reported to range between 11,300 (0.4 per 10,000, gastric cancer) and 92,000 patients (2.9 per 10,000, lung cancer).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: